Abstract OBJECTIVE: To study serum acylation-stimulating protein (ASP) and complement 3 (C3) levels and their relationship with blood lipids in children with primary nephrotic syndrome (PNS). METHODS: Blood samples were obtained from 35 PNS children with proteinuria, 25 children with PNS at remission and 35 body mass index-matched healthy children (control group). Fasting serum ASP, C3, albumin and blood lipids were measured. RESULTS: The serum ASP levels in the proteinuria group (101±22 nmol/L) were significantly higher than those in the remission group (32±8 nmol/L) and the control group (33± 8 nmol/L) (P0.05). CONCLUSIONS: The increased serum ASP level may be associated with a complemental mechanism against hyperlipidemia in children with PNS.
WANG Jian-Jun,HUANG Yue,WU Chun et al. Levels of serum acylation-stimulating protein and C3 in children with primary nephrotic syndrome[J]. 中国当代儿科杂志, 2011, 13(10): 817-819.
WANG Jian-Jun,HUANG Yue,WU Chun et al. Levels of serum acylation-stimulating protein and C3 in children with primary nephrotic syndrome[J]. CJCP, 2011, 13(10): 817-819.
［4］Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE)［J］. Pediatrics, 2000, 105(6): 1242-1249.
［5］Chan MK, Persaud JW, Ramdial L, Varghese Z, Sweny P, Moorhead JF. Hyperlipidaemia in untreated nephritic syndrome, increased production or decreased removal?［J］. Clin Chim Acta, 1981, 117(3): 317-323.
［6］Hu P, Lu L, Hu B, Du PF. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephritic syndrome［J］. Scand J Clin Lab Invest, 2009, 69(6): 680-686.
［7］Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease［J］. J Am Soc Nephrol, 2002, 13(1): 134-141.
［9］Cianflone K, Maslowska M, Snideman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions［J］. Semin Cell Dev Biol, 1999, 10(1): 31-41.
［10］Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents［J］. Biochim Biophys Acta, 2003, 1609(2): 127-143.
［11］Ozata M, Oktenli C, Gulec M, Ozgurtas T, Bulucu F, Caglar K, et al. Increased fasting plasma acylation-stimulating protein concentrations in nephritic syndrome［J］. J Clin Endocrinol Metab, 2002, 87(2): 853-858.
［12］Tang JH, Wen Y, Wu F, Zhao XY, Zhang MX, Mi J, et al. Increased plasma acylation-stimulating protein in pediatric proteinuric renal disease［J］. Pediatr Nephrol, 2008, 23(6): 959-964.
